Phase I Study of AR-42 in Relapsed Myeloma, Chronic Lymphocytic Leukemia, and Lymphoma

Trial Profile

Phase I Study of AR-42 in Relapsed Myeloma, Chronic Lymphocytic Leukemia, and Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs AR 42 (Primary)
  • Indications Acute myeloid leukaemia; Cancer; Chronic lymphocytic leukaemia; Hodgkin's disease; Leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 21 Feb 2017 Planned End Date changed from 1 Dec 2016 to 31 Dec 2017.
    • 07 Jun 2016 Results (n=17) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 16 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top